• 1
    Nelson DR, Koymans L, Kamataki T,et al.P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature.Pharmacogenetics1996; 6: 142
  • 2
    Wrighton SA, Stevens JCThe human hepatic cytochromes P450 involved in drug metabolism.Crit Rev Toxicol1992; 22: 121
  • 3
    Gonzalez FJHuman cytochromes P450: Problems and prospects.Trends Pharmacol Sci1992; 13: 346352
  • 4
    Cholerton S, Daly AK, Idle JRThe role of individual human cytochromes P450 in drug metabolism and clinical response.Trends Pharmacol Sci1992; 13: 434439
  • 5
    Gonzalez FJMolecular genetics of the P450 superfamily.Pharmacol Ther1990; 45: 138
  • 6
    Miners JO, Veronese ME, Birkett DJIn vitro approaches for the prediction of human drug metabolism.Ann Reports Med Chem1994; 29: 307316
  • 7
    Birkett DJ, Mackenzie PI, Veronese ME, Miners JOIn vitro approaches can predict human drug metabolism.Trends Pharmacol Sci1993; 14: 292294
  • 8
    Ged C, Umbenhauer DR, Bellew TM,et al.Characterization of cDNAs, mRNAs and proteins related to human liver microsomal cytochrome P450 (S)-mephenytoin 4′–hydroxylase.Biochemistry1988; 27: 69296940
  • 9
    Goldstein JA, De Morais SMFBiochemistry and molecular biology of the human CYP2C subfamily.Pharmacogenetics1994; 4: 285299
  • 10
    Wang P, Beaune P, Kaminsky LS,et al.Purification and characterization of six cytochrome P450 isozymes from human liver microsomes.Biochemistry1983; 22: 53755383
  • 11
    Shimada T, Misono KS, Guengerich FPHuman liver microsomal cytochrome P450 mephenytoin 4′–hydroxylase, a prototype genetic polymorphism of drug metabolism: Purification and characterization of two similar forms involved in the reaction. J Biol Chem 1986; 261: 909921
  • 12
    Kimura S, Pastewka J, Gelboin HV, Gonzalez FJcDNA and amino acid sequences of two members of the human IIC gene subfamily.Nucleic Acids Res1987; 15: 10053–10054
  • 13
    Meehan RR, Gosden JR, Rout D,et al.Human cytochrome P450 PB-1: A multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.Am J Human Genet1988; 42: 2637
  • 14
    Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JACloning and expression of complementary DNAs for multiple members of the human cytochrome P450 IIC subfamily.Biochemistry1991; 30: 32473255
  • 15
    Veronese ME, Doecke CJ, Mackenzie PI,et al.Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily.Biochem J1993; 289: 533538
  • 16
    Umbenhauer DR, Martin MV, Lloyd RS, Guengerich FPCloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P450 S-mephenytoin 4′–hydroxylase. Biochemistry1987; 26: 10941099
  • 17
    Yasumori TS, Kawano K, Nagata M, Shimada Y, Yamazoe Y, Kato RNucleotide sequence of a human liver cytochrome P450 related to the male rat specific form.J Biochem (Tokyo)1987; 102: 10751082
  • 18
    Gotoh OSubstrate recognition sites in cytochrome P-450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.J Biol Chem1992; 267: 8390
  • 19
    Wong BK, Goldstein J, Spielberg SP, Rushmore THCharacterisation of an in vitro model for assessing polymorphic metabolism by CYP2C9: Involvement in the mechanism of deficient losartan metabolism.ISSX Proceedings1996; 10: 236
  • 20
    Haining RL, Jones JP, Koop DR, Trager WF, Rettie AEDeterminants of substrate and inhibitor specificities of human CYP2C9.ISSX Proceedings1996; 10: 239
  • 21
    Korzekwa K, Jones JPPredicting the cytochrome P450 mediated metabolism of xenobiotics.Pharmacogenetics1993; 3: 118
  • 22
    Mancy A, Broto P, Dijols S, Dansette PM, Mansuy DThe substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modeling.Biochemistry1995; 34: 10365–10375
  • 23
    Jones BC, Hawksworth G, Horne VA,et al.Putative active site model for cytochrome P4502C9 (tolbutamide hydroxylase).Drug Metab Dispos1996; 24: 260266
  • 24
    Jones JP, He M, Trager WF, Rettie AEThree dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.Drug Metab Dispos1996; 24: 16
  • 25
    Shou M, Krausz KW, Gonzalez FJ, Gelboin HVMetabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450.Arch Biochem Biophys1996; 238: 201207
  • 26
    Gautier J-C, Lecoeur S, Cosme J,et al.Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7, 8-dihydrodiol metabolism, as predicted from heterologous expression in yeast.Pharmacogenetics1996; 6: 489499
  • 27
    Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJTolbutamide hydroxylation by human liver microsomes: Kinetic characterisation and relationship to other cytochrome P450 dependent xenobiotic oxidations.Biochem Pharmacol 1988; 37: 11371144
  • 28
    Back DJ, Tjia JF, Karbwang J, Colberg JIn vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolones.Br J Clin Pharmacol1988 25: 2329
  • 29
    Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJTolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.Biochem Biophys Res Commun1991; 175: 11121118
  • 30
    Miners JO, Birkett DJThe use of tolbutamide as a substrate probe for human hepatic cytochrome P4502C9.Methods Enzymol1996; 272: 139145
  • 31
    Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJKetoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9.Xenobiotica 1995; 25: 261270
  • 32
    Veronese ME, Miners JO, Randles D, Birkett DJValidation of the tolbutamide metabolic ratio for population screening with use of sulphaphenazole to produce model phenotypic poor metabolisers.Clin Pharmacol Ther1990; 47: 403411
  • 33
    Back DJ, Tjia J, Ohnhaus EE, Park BKSelective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.Eur J Clin Pharmacol1998; 34: 157163
  • 34
    Pond SM, Birkett DJ, Wade DNMechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulphaphenazole.Clin Pharmacol Ther1977; 22: 573579
  • 35
    Thomas RC, Ikeda GJThe metabolic fate of tolbutamide in man and in the rat.J Med Chem1966; 9: 507510
  • 36
    Nelson E, O'Reilly IKinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration.J Pharmacol Exp Ther1961; 132: 103109
  • 37
    Doecke CJ, Veronese ME, Pond SM,et al.Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.Br J Clin Pharmacol1991; 31: 125130
  • 38
    Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJHuman hepatic cytochrome P4502C9 catalyzes the rate-limiting pathway of torsemide metabolism.J Pharmacol Exp Ther1995; 272: 10761081
  • 39
    Relling MV, Aoyama T, Gonzalez FJ, Meyer UATolbutamide and mephenytoin hydroxylation by human cytochromes P450 in the CYP2C subfamily.J Pharmacol Exp Ther1990; 252: 442447
  • 40
    Tassaneeyakul WPhD Thesis, Flinders University of South Australia 1994.
  • 41
    Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire B.Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.Ther Drug Monit1985; 7: 283289
  • 42
    Molholm-Hansen J, Kampmann JP, Siersbaek-Nielsen K,et al. The effect of different sulphonamides on phenytoin metabolism in man.Acta Med Scand1979; suppl 624: 106110
  • 43
    Hall SD, Hamman MA, Rettie AE,et al.Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.Drug Metab Dispos1994; 22: 975978
  • 44
    Tassaneeyakul W, Veronese ME, Birkett DJ,et al.Co-regulation of phenytoin and tolbutamide metabolism in humans.Br J Clin Pharmacol1992; 34: 494498
  • 45
    Toon S, Low LK, Gibaldi M,et al.The warfarin-sulfinpyrazole interaction: stereochemical considerations.Clin Pharmacol Ther1986; 39: 1524
  • 46
    Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WFHydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role for P4502C9 in the etiology of (S)-warfarin drug interactions.Chem Res Toxicol1992; 5: 5459
  • 47
    Kunze KL, Wienkers LC, Thummel KF, Trager WFWarfarin-fluconazole I. Inhibition of human cytochrome P450 dependent metabolism of warfarin by fluconazole: in vitro studies.Drug Metab Dispos1996; 24: 414421
  • 48
    Hamman MA, Thompson GA, Hall SDRegioselective and stereoselective metabolism of ibuprofen by human cytochrome P4502C.Biochem Pharmacol1997; 54: 3341
  • 49
    Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KRRole of cytochrome P4502C9 and an allelic variant in the 4′–hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol1995; 49: 12691275
  • 50
    Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJCytochromes P450 1A2 and 2C9 are responsible for the human hepatic O-demethylation of (R)- and (S)-naproxen.Biochem Pharmacol1996; 51: 10031008
  • 51
    Rodrigues AD, Kukulka MJ, Roberts EM, Ouellet D, Rodgers TR,[O-methyl14C]naproxen O-demethylase activity in human liver microsomes. Evidence for the involvement of cytochrome P4501A2 and P4502C9/10.Drug Metab Dispos1996; 24: 126136
  • 52
    Miners JO, Mackenzie PIDrug glucuronidation in humans.Pharmacol Ther1991; 51: 347369
  • 53
    Leemann T, Transom C, Dayer PCytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′–hydroxylation in human liver.Life Sci1993; 52: 2934
  • 54
    Bonnabry P, Leemann T, Dayer PRole of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.Eur J Clin Pharmacol1996; 49: 305308
  • 55
    Zhao J, Leemann T, Dayer PIn vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450.Life Sci1992; 51: 575581
  • 56
    Bonnabry P, Leemann T, Dayer PBiotransformation by hepatic P450TB (CYP2C) controls mefenamic acid elimination.Clin Pharmacol Ther1994; 55: 139
  • 57
    Bort R, Ponsoda E, Carrasco E, Gomez-Lechon MJ, Castell JVMetabolism of aceclofenac in humans.Drug Metab Dispos1996; 24: 834841
  • 58
    Neugebauer G, Bessenfelder E, Von Mollendorff EPharmacokinetics and metabolism of torsemide in man.Arzneim.-Forsch1988; 38: 164166
  • 59
    Lopez Garcia MP, Dansette PM, Valadon P,et al.Human liver cytochromes P450 expressed in yeast as tools for reactive metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P450 2C9 and 2C10.Eur J Biochem1993; 213: 223232
  • 60
    Dansette PM, Amar C, Valadon P, Pons C, Beaune PH, Mansuy DHydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation.Biochem Pharmacol1991; 41: 553560
  • 61
    Lecouer S, Andre C, Beune PHTienilic-induced autoimmune hepatitis: Anti-liver and -kidney microsomal type 2 autoantibodies recognise a three-site conformational epitope on cytochrome P4502C9.Mol Pharmacol1996; 50: 326333
  • 62
    Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GTCytochromes P450 mediating the N-demethylation of amitriptyline.Br J Clin Pharmacol1997; 43: 137144
  • 63
    Von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Harmatz JS, Shader RIHuman cytochromes mediating N-demethylation of fluoxetine in vitro.Clin Pharmacol Ther1997; 61: 177
  • 64
    Stearns RA, Chakravarty PK, Chen R, Chui S-HLBiotransformation of losartan to its active carboxylic metabolite in human liver microsomes. Role of cytochrome P450 2C and 3A subfamily members.Drug Metab Dispos1995; 23: 207215
  • 65
    Kumar GN, Dubberke E, Rodrigues AD, Roberts E, Dennisen JFIdentification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001).Drug Metab Dispos1997; 25: 110115
  • 66
    Bornheim LM, Lasker JM, Raucy JLHuman hepatic microsomal metabolism of Δ1-tetrahydrocannabinol. Drug Metab Dispos1992; 20: 241246
  • 67
    Weaver RJ, Dickins M, Burke MDCytochrome P4502C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver.Biochem Pharmacol1993; 46: 11831197
  • 68
    Weaver RT, Dickins M, Burke MDHydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: Comparison with mephenytoin and tolbutamide hydroxylations.Biochem Pharmacol1995; 49: 9971004
  • 69
    Jones CR, Guengerich FP, Rice JM, Lubet RAInduction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates.Pharmacogenetics1992; 2: 160172
  • 70
    Serlin MJ, Breckinridge AMDrug interactions with warfarin.Drugs1983; 25: 610620
  • 71
    Nation RL, Evans AM, Milne RWPharmacokinetic drug interactions with phenytoin.Clin Pharmacokinet1990; 18: 3760
  • 72
    Oda Y, Yoshida N, Nishi S,et al.Effect of high dose barbiturate therapy on phenytoin pharmacokinetics.Clin Pharmacol Ther1992; 51: 187
  • 73
    Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, McWilliams EJ, McCrea JBPhenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174.Clin Pharmacol Ther1996; 59: 268274
  • 74
    Baciewicz AMCarbamazepine drug interactions.Therapeutic Drug Monit1986; 8: 305317
  • 75
    Iber FLDrug metabolism in heavy consumers of ethyl alcohol.Clin Pharmacol Ther1977; 22: 735742
  • 76
    Kater RMH, Roggin G, Tobon F, Zieve P, Iber FLIncreased rate of clearance of drugs from the circulation of alcoholics.Am J Med Sci1969; 258: 3539
  • 77
    Sandor P, Sellers EM, Dumbrell M, Khouw VEffect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.Clin Pharmacol Ther1981; 30: 390397
  • 78
    Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DAThe mechanism of the warfarin-rifampin drug interaction in humans.Clin Pharmacol Ther1987; 42: 388394
  • 79
    Zilly W, Breimer DD, Richter EInduction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.Eur J Clin Pharmacol1975; 9: 219227
  • 80
    Kay L, Kampmann JP, Svendsen TL,et al.Influence of rifampicin and isoniazid on the kinetics of phenytoin.Br J Clin Pharmacol1985; 20: 323326
  • 81
    Williamson KM, Patterson JH, Pieper JA, McQueen RH, Adams KFEffects of erythromycin or rifampin on steady state losartan kinetics in healthy volunteers.Clin Pharmacol Ther1997; 61: 202
  • 82
    Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear KPharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers.Clin Pharmacol Ther1989; 46: 4350
  • 83
    O'Reilly RA, Trager WF, Rettie AE, Goulart DAInteraction of amiodarone with racaemic warfarin and its separated enantiomorphs in humans.Clin Pharmacol Ther1987; 42: 290294
  • 84
    Heimark LD, Wienkers L, Kunze K,et al.The mechanism of the interaction between amiodarone and warfarin in humans.Clin Pharmacol Ther1992; 51: 398407
  • 85
    Skovsted L, Kristensen M, Hansen JM, Siersbaek-Nielsen KThe effect of different oral anticoagulants on diphenylhydration and tolbutamide metabolism.Acta Med Scand1976; 199: 513515
  • 86
    Serlin MJ, Mossman S, Sibeon RG,et al.Cimetidine: Interaction with oral anticoagulants in man.Lancet1979; ii: 317319
  • 87
    Toon S, Hopkins KJ, Garstang FM, Rowland MComparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.Eur J Clin Pharmacol1987; 32: 165172
  • 88
    Niopas I, Toon S, Rowland MFurther insight into the stereoselective interaction between warfarin and cimetidine in man.Br J Clin Pharmacol1991; 32: 508511
  • 89
    Hargreaves JA, Jezequel S, Houston JBEffect of azole antifungals on human microsomal metabolism of diclofenac and midazolam.Br J Clin Pharmacol1994; 38: 175P.
  • 90
    Kazierad DJ, Martin DE, Tenero D,et al.Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan.Clin Pharmacol Ther1997; 61: 203
  • 91
    Blum RA, Wilton JH, Hilligoss DM,et al.Effect of fluconazole on the disposition of phenytoin.Clin Pharmacol Ther1991; 49: 420425
  • 92
    Lazar JD, Wilner KDDrug interactions with fluconazole.Rev Infec Dis1990; 12(Suppl 3): S327–S333
  • 93
    Black DJ, Kunze KL, Wienkers LC,et al.Warfarin-fluconazole II. A metabolically based drug interaction.Drug Metab Dispos1996; 24: 422428
  • 94
    Kunze KL, Trager WFWarfarin-fluconazole III. A rational approach to management of a metabolically based drug interaction.Drug Metab Dispos1996; 24: 429435
  • 95
    O'Reilly RA, Goulart DA, Kunze KL,et al.Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.Clin Pharmacol Ther1992; 51: 656667
  • 96
    Back DJ, Stevenson P, Tjia JFComparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes.Br J Clin Pharmacol1989; 28: 166170
  • 97
    McCrea JB, Lo MW, Furtek CI,et al.Ketoconazole does not affect the systemic conversion of losartan to E-3174.Clin Pharmacol Ther1996; 59: 169
  • 98
    Touchette MA, Chandrasekar PH, Milad MA, Edwards DJContrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.Br J Clin Pharmacol1992; 34: 7578
  • 99
    Transon C, Leeman R, Dayer PIn vitro comparative inhibition profiles of major drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6, CYP3A4) by HMG-CoA reductase inhibitors.Eur J Clin Pharmacol1996; 50: 209215
  • 100
    Transon C, Leeman R, Vogt N, Dayer PIn vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin.Clin Pharmacol Ther1995; 58: 412417
  • 101
    Lewis RJ, Trager WF, Chan KE,et al.Warfarin—Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest1974; 53: 16071617
  • 102
    Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJThe effect of sulphinpyrazone on oxidative drug metabolism in man: Inhibition of tolbutamide elimination.Eur J Clin Pharmacol1982; 22: 321326
  • 103
    Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJInteraction of sulphinpyrazone with warfarin.Eur J Clin Pharmacol1982; 22: 327331
  • 104
    He M, Kunze KL, Trager WFInhibition of S-warfarin metabolism by sulfinpyrazone and its metabolites.Drug Metab Dispos1995; 23: 659663
  • 105
    Christensen LK, Hansen JM, Kristensen MSulphaphenazole-induced hypoglycaemic attacks in tolbutamide-treated diabetics.Lancet1963; 2: 12981301
  • 106
    Hansen JM, Kampmann JP, Siersbaek-Nielsen K,et al.The effect of different sulfonamides on phenytoin metabolism in man.Acta Med Scand1979; 24(Suppl 6): 106110
  • 107
    Wing LMH, Miners JOCotrimoxazole as an inhibitor of oxidative drug metabolism: Effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.Br J Clin Pharmacol1985; 20: 482485
  • 108
    Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Molholm-Hansen JSulfamethizole-induced inhibition of diphenylhydratoin, tolbutamide and warfarin metabolism.Clin Pharmacol Ther1975; 17: 731734
  • 109
    Suttle AB, Vargo DL, Wilkinson LA, Birmingham BK, Lasseter KEffect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men.Clin Pharmacol Ther1997; 61: 186
  • 110
    Miners JO, Wing LMH, Lillywhite KJ, Smith KJFailure of therapeutic doses of ß-adrenoreceptor antagonists to alter the disposition of tolbutamide and lignocaine. Br J Clin Pharmacol1984; 18: 853860
  • 111
    Robson RA, Miners JO, Whitehead AG, Birkett DJSpecificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism: Lack of effect on theophylline and tolbutamide disposition.Br J Clin Pharmacol1987; 23: 772776
  • 112
    Abernethy DR, Kaminsky LS, Dickinson THSelective inhibition of warfarin metabolism by diltiazem in humans1991;257: 411416
  • 113
    Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland MEnoxacin-warfarin interaction: Pharmacokinetic and stereochemical aspects.Clin Pharmacol Ther1987; 42: 3341
  • 114
    Milne RW, Coulthard K, Nation RL, Penna AC, Roberts G, Sansom LNLack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.Br J Clin Pharmacol1988; 26: 330333
  • 115
    Jensen JC, Gugler RInteraction between metronidazole and drugs eliminated by oxidative metabolism.Clin Pharmacol Ther1985; 37: 407410
  • 116
    Maya JF, Callaghan JT, Bergstrom RF, Cerimele BJ, Kassahun K, Nyhart EHOlanzapine and warfarin drug interaction.Clin Pharmacol Ther1997; 61: 182
  • 117
    Andersson T, Lagerstrom P-O, Unge PA study of the interaction between omeprazole and phenytoin in epileptic patients.Ther Drug Monit1990; 12: 329333
  • 118
    Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen OStereoselective interaction of omeprazole with warfarin in healthy men.Ther Drug Monit1989; 11: 176184
  • 119
    Scott J, Poffenbarger PLPharmacogenetics of tolbutamide metabolism in humans.Diabetes1979;28: 4151
  • 120
    Back DJ, Orme ML’EGenetic factors influencing the metabolism of tolbutamide.Pharmacol Ther1989; 44: 147155
  • 121
    Miners JO, Wing LMH, Birkett DJNormal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.Aust NZ J Med1985; 15: 348349
  • 122
    Sullivan-Klose TH, Ghanayem BI, Bell DA,et al.The role of the CYP2C9-Leu (359) allelic variant in the tolbutamide polymorphism.Pharmacogenetics1996; 6: 341349
  • 123
    Page MA, Boutagy JS, Shenfield GMA screening test for slow metabolisers of tolbutamide.Br J Clin Pharmacol1991; 31: 649654
  • 124
    Veronese ME, Miners JO, Rees DLP, Birkett DJTolbutamide hydroxylation in humans: Lack of biomodality in 106 healthy subjects.Pharmacogenetics1993; 3: 8693
  • 125
    Vermeij P, Ferrari MD, Buruma JS, Veenema H, DeWolff FAInheritance of poor phenytoin parahydroxylation capacity in a Dutch family.Clin Pharmacol Ther1988; 44: 588593
  • 126
    Inaba TPhenytoin: Pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther1990; 46: 341347
  • 127
    Spielberg S, McCrea J, Cribb A,et al.A mutation in CYP2C9 is responsible for decreased metabolism of losartan.Clin Pharmacol Ther1996; 59: 215
  • 128
    Bhasker CR, Miners JO, Coulter S, Birkett DJAllelic and functional variability of cytochrome P4502C9.Pharmacogenetics1997; 7: 5158
  • 129
    Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CRGenetic analysis of the human cytochrome P4502C9 locus.Pharmacogenetics1996; 6: 429439
  • 130
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada TRelationship between CYP 2C9 and 2C19 genotypes and tolbutamide methylhydroxylation and S-mephenyotin 4′–hydroxylation activities in livers of Japanese and Caucasian populations.Pharmacogenetics1997; 7: 103113
  • 131
    Wang S-L, Huang J-D, Lai M-D, Tsai J-JDetection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.Pharmacogenetics1995; 5: 3742
  • 132
    Nasu K, Kubota T, Ishizaki TGenetic analysis of CYP2C9 polymorphism in a Japanese population.Pharmacogenetics1997; 7: 405409
  • 133
    Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AEAllelic variants of human cytochrome P4502C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.Arch Biochem Biophys1996; 333: 447458
  • 134
    Steward DJ, Haining RL, Henne KR,et al.Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics1997; 7: 361367
  • 135
    Kaminsky LS, DeMorais S, Faletto MB, Dunbar DA, Goldstein JACorrelation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe.Mol Pharmacol1993; 43: 234239
  • 136
    Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KRImpaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.Pharmacogenetics1994; 4: 3942
  • 137
    Crespi CR, Miller VPThe R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase.Pharmacogenetics1997; 7: 203210
  • 138
    Furuya H, Fernandez-Salguero P, Gregory W,et al.Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.Pharmacogenetics1995; 5: 389392
  • 139
    London SJ, Sullivan-Klose T, Daly AK, Idle JRLung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.Pharmacogenetics1997; 7: 401404
  • 140
    Furuya H, Meyer UA, Gelboin HV, Gonzalez FJPolymerase chain reaction directed identification, cloning and quantitation of CYP2C18 mRNA.Mol Pharmacol1991; 40: 375382
  • 141
    DeMorais SMF, Schweiki H, Blaisdell J, Goldstein JAGene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.Biochem Biophys Res Commun1993; 194: 194201
  • 142
    Ibeanu GC, Goldstein JATranscriptional regulation of human CYP2C genes: Functional comparison of CYP2C9 and CYP2C18 promoter regions.Biochemistry1995; 34: 80288036
  • 143
    Shimada T, Yamazaki H, Mimura M,et al.Characterisation of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs.Drug Metab Dispos1996; 24: 515522
  • 144
    Hakkola J, Pasanen M, Hukkanen J,et al.Expression of xenobiotic-metabolising cytochrome P450 forms in human full-term placenta.Biochem Pharmacol1996; 51: 403411
  • 145
    Hakkola J, Pasanen M, Purkunen R,et al.Expression of xenobiotic metabolising cytochrome P450 forms in human adult and fetal liver.Biochem Pharmacol1994; 48: 5964
  • 146
    Ratanasavanh D, Beaune P, Morel F, Flinois J-P, Guengerich FP, Guillouzo AIntralobular distribution and quantitation of cytochrome P450 enzymes in human liver as a function of age.Hepatology1991; 13: 11421151
  • 147
    Morrow JI, Richens ADisposition of anticonvulsants in children.Clin Pharmacokinet 1989; 17(Suppl 1): 89104
  • 148
    Loi C-M, Vestal REDrug metabolism in the elderly.Pharmacol Ther1988; 36: 131149
  • 149
    Horn JR, Wittkowsky AK, Linenberger M, Greenberg D, Meade DM, Lam AEffect of age on disposition of warfarin enantiomers.Clin Pharmacol Ther1997; 61: 175
  • 150
    Harris RZ, Benet LZ, Schwartz JBGender effects in pharmacokinetics and pharmacodynamics.Drugs1995; 50: 222239
  • 151
    Chan E, Ti TY, Lee HSPopulation pharmacokinetics of phenytoin in Singapore Chinese.Eur J Clin Pharmacol1990; 39: 177181
  • 152
    Grasela TH, Sheiner LB, Rambeck B,et al.Steady-state pharmacokinetics of phenytoin from routinely collected patient data.Clin Pharmacokinet1983; 8: 355364
  • 153
    James AH, Britt RP, Raskino CL, Thompson SGFactors affecting the maintenance doses of warfarin.J Clin Pathol1992; 45: 704706
  • 154
    Chen L, Yasumori T, Yamazoe Y, Kato RHepatic microsomal tolbutamide hydroxylation in Japanese: In vitro evidence for rapid and slow metabolisers.Pharmacogenetics1993; 3: 7785